



US007265119B2

(12) **United States Patent**
Bogle et al.

(10) **Patent No.:** **US 7,265,119 B2**
(45) **Date of Patent:** **Sep. 4, 2007**

(54) **TARTRATE SALTS OF
5,8,14-TRIAZATETRACYCLO[10.3.1.0^{2,11}.0^{4,9}]-
HEXADECA-2(11),3,5,7,9-PENTAENE AND
PHARMACEUTICAL COMPOSITIONS
THEREOF**

FOREIGN PATENT DOCUMENTS

EP	1078637	2/2001
WO	WO 9935131	7/1999

(75) Inventors: **David E. Bogle**, Jewett City, CT (US);
Glenn R. Williams, Oaksville (CA);
Peter R. Rose, Ledyard, CT (US)

(73) Assignee: **Pfizer Inc.**, New York, NY (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 105 days.

(21) Appl. No.: **11/069,724**

(22) Filed: **Feb. 28, 2005**

(65) **Prior Publication Data**

US 2005/0148591 A1 Jul. 7, 2005

Related U.S. Application Data

(63) Continuation of application No. 10/139,730, filed on
May 6, 2002, now Pat. No. 6,890,927.

(60) Provisional application No. 60/290,861, filed on May
14, 2001.

(51) **Int. Cl.**
C07D 241/36 (2006.01)
A61K 31/50 (2006.01)
A61K 31/495 (2006.01)

(52) **U.S. Cl.** **514/250; 544/343**

(58) **Field of Classification Search** 544/343;
514/250

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,471,503 A 10/1969 Carson

OTHER PUBLICATIONS


Paul H. Mazzochi, et al., "Synthesis and Pharmacological Activity
of 2,3,4,5-Tetrahydro-1,5-Methano-1H-3-Benzazepines", J. Med.
Chem., vol. 22, No. 4, 1979, pp. 455-457, XP002090422.

Primary Examiner—Bruck Kifle

(74) *Attorney, Agent, or Firm*—Steve T. Zelson; A. David
Joran

(57) **ABSTRACT**

The present invention is directed to the tartrate salts of
5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]-hexadeca-2(11),3,
5,7,9-pentaene:



and pharmaceutical compositions thereof. The present
invention in particular is directed to the L-tartrate salt, and
further to the various polymorphs of the L-tartrate salt,
including two distinct anhydrous polymorphs (referred to
herein as Forms A and B) and a hydrate polymorph (referred
to herein as Form C). In addition, the present invention is
also directed to the D-tartrate salt of 5,8,14-triazatetracyclo
[10.3.1.0^{2,11}.0^{4,9}]-hexadeca-2(11),3,5,7,9-pentaene and the
various polymorphs thereof; as well as the D,L-tartrate salt
thereof and its polymorphs, and the meso-tartrate salt thereof
and its polymorphs.

15 Claims, 20 Drawing Sheets